Market News AIOpen the app

TVTX stock news · Travere Therapeutics

Stories about Travere Therapeutics (TVTX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for TVTX

Follow Travere Therapeutics (TVTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TVTX
Free on the App Store and Google Play, or on the web.
  1. Nov 2, 2026, 5:44 PM ET · Results

    Travere Therapeutics shared its Q3 results, showing product sales over $200 million thanks to strong demand for FILSPARI.

    Good for TVTX

    Travere’s quarterly product sales topped $200 million for the first time as FILSPARI demand grew. This supports a stronger outlook for the company.

  2. Oct 23, 2026, 1:44 PM ET · Market

    Big investors are making moves in 10 health care stocks today.

    Neutral

    The alert marked Travere Therapeutics' call trade bearish. It reports trading activity, not a company change, so it does not change the company's outlook.

  3. Oct 13, 2026, 11:13 AM ET · Market

    The FTC claims Martin Shkreli broke his lifetime ban from the drug industry by trading stock.

    Neutral

    The FTC and 7 states accuse Martin Shkreli of breaking his lifetime drug-industry ban. Travere is mentioned for its past link to him, but no business effect is reported.